Intraclonal complexity in chronic lymphocytic leukemia: Fractions enriched in recently born/divided and older/quiescent cells

Carlo Calissano, Rajendra N. Damle, Sonia Marsilio, Xiao Jie Yan, Sophia Yancopoulos, Gregory Hayes, Claire Emson, Elizabeth J. Murphy, Marc K. Hellerstein, Cristina Sison, Matthew S. Kaufman, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Ivana Ivanovic, Igor M. Dozmorov, Sergio Roa, Matthew D. Scharff, Wentian Li, Nicholas Chiorazzi

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth of minor subclones with more dangerous genomic abnormalities or with self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured B-cell kinetics in vivo by quantifying deuterium ( 2H)-labeled cells as an indicator of a cell that had divided. Separating CLL clones on the basis of reciprocal densities of chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster designation 5 (CD5) revealed that the CXCR4 dimCD5 bright (proliferative) fraction contained more 2H-labeled DNA and hence divided cells than the CXCR4 brightCD5 dim (resting) fraction. This enrichment was confirmed by the relative expression of two cell cycle-associated molecules in the same fractions, Ki-67 and minichromosome maintenance protein 6 (MCM6). Comparisons of global gene expression between the CXCR4 dimCD5 bright and CXCR4 brightCD5 dim fractions indicated higher levels of pro-proliferation and antiapoptotic genes and genes involved in oxidative injury in the proliferative fraction. An extended immunophenotype was also defined, providing a wider range of surface molecules characteristic of each fraction. These intraclonal analyses suggest a model of CLL cell biology in which the leukemic clone contains a spectrum of cells from the proliferative fraction, enriched in recently divided robust cells that are lymphoid tissue emigrants, to the resting fraction enriched in older, less vital cells that need to immigrate to lymphoid tissue or die. The model also suggests several targets preferentially expressed in the two populations amenable for therapeutic attack. Finally, the study lays the groundwork for future analyses that might provide a more robust understanding of the development and clonal evolution of this currently incurable disease. © 2011 The Feinstein Institute for Medical Research.

Original languageEnglish (US)
Pages (from-to)1374-1382
Number of pages9
JournalMolecular Medicine
Volume17
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Lymphoid Tissue
CCR Receptors
Minichromosome Maintenance Proteins
Clone Cells
Clonal Evolution
Deuterium
Genes
Cell Biology
Biomedical Research
Cell Cycle
B-Lymphocytes
Gene Expression
DNA
Wounds and Injuries
Population
Neoplasms

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Calissano, C., Damle, R. N., Marsilio, S., Yan, X. J., Yancopoulos, S., Hayes, G., ... Chiorazzi, N. (2011). Intraclonal complexity in chronic lymphocytic leukemia: Fractions enriched in recently born/divided and older/quiescent cells. Molecular Medicine, 17(11), 1374-1382. https://doi.org/10.2119/molmed.2011.00360

Intraclonal complexity in chronic lymphocytic leukemia : Fractions enriched in recently born/divided and older/quiescent cells. / Calissano, Carlo; Damle, Rajendra N.; Marsilio, Sonia; Yan, Xiao Jie; Yancopoulos, Sophia; Hayes, Gregory; Emson, Claire; Murphy, Elizabeth J.; Hellerstein, Marc K.; Sison, Cristina; Kaufman, Matthew S.; Kolitz, Jonathan E.; Allen, Steven L.; Rai, Kanti R.; Ivanovic, Ivana; Dozmorov, Igor M.; Roa, Sergio; Scharff, Matthew D.; Li, Wentian; Chiorazzi, Nicholas.

In: Molecular Medicine, Vol. 17, No. 11, 11.2011, p. 1374-1382.

Research output: Contribution to journalArticle

Calissano, C, Damle, RN, Marsilio, S, Yan, XJ, Yancopoulos, S, Hayes, G, Emson, C, Murphy, EJ, Hellerstein, MK, Sison, C, Kaufman, MS, Kolitz, JE, Allen, SL, Rai, KR, Ivanovic, I, Dozmorov, IM, Roa, S, Scharff, MD, Li, W & Chiorazzi, N 2011, 'Intraclonal complexity in chronic lymphocytic leukemia: Fractions enriched in recently born/divided and older/quiescent cells', Molecular Medicine, vol. 17, no. 11, pp. 1374-1382. https://doi.org/10.2119/molmed.2011.00360
Calissano, Carlo ; Damle, Rajendra N. ; Marsilio, Sonia ; Yan, Xiao Jie ; Yancopoulos, Sophia ; Hayes, Gregory ; Emson, Claire ; Murphy, Elizabeth J. ; Hellerstein, Marc K. ; Sison, Cristina ; Kaufman, Matthew S. ; Kolitz, Jonathan E. ; Allen, Steven L. ; Rai, Kanti R. ; Ivanovic, Ivana ; Dozmorov, Igor M. ; Roa, Sergio ; Scharff, Matthew D. ; Li, Wentian ; Chiorazzi, Nicholas. / Intraclonal complexity in chronic lymphocytic leukemia : Fractions enriched in recently born/divided and older/quiescent cells. In: Molecular Medicine. 2011 ; Vol. 17, No. 11. pp. 1374-1382.
@article{608cc199c3ab4c6e9f791fbc6e883736,
title = "Intraclonal complexity in chronic lymphocytic leukemia: Fractions enriched in recently born/divided and older/quiescent cells",
abstract = "The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth of minor subclones with more dangerous genomic abnormalities or with self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured B-cell kinetics in vivo by quantifying deuterium ( 2H)-labeled cells as an indicator of a cell that had divided. Separating CLL clones on the basis of reciprocal densities of chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster designation 5 (CD5) revealed that the CXCR4 dimCD5 bright (proliferative) fraction contained more 2H-labeled DNA and hence divided cells than the CXCR4 brightCD5 dim (resting) fraction. This enrichment was confirmed by the relative expression of two cell cycle-associated molecules in the same fractions, Ki-67 and minichromosome maintenance protein 6 (MCM6). Comparisons of global gene expression between the CXCR4 dimCD5 bright and CXCR4 brightCD5 dim fractions indicated higher levels of pro-proliferation and antiapoptotic genes and genes involved in oxidative injury in the proliferative fraction. An extended immunophenotype was also defined, providing a wider range of surface molecules characteristic of each fraction. These intraclonal analyses suggest a model of CLL cell biology in which the leukemic clone contains a spectrum of cells from the proliferative fraction, enriched in recently divided robust cells that are lymphoid tissue emigrants, to the resting fraction enriched in older, less vital cells that need to immigrate to lymphoid tissue or die. The model also suggests several targets preferentially expressed in the two populations amenable for therapeutic attack. Finally, the study lays the groundwork for future analyses that might provide a more robust understanding of the development and clonal evolution of this currently incurable disease. {\circledC} 2011 The Feinstein Institute for Medical Research.",
author = "Carlo Calissano and Damle, {Rajendra N.} and Sonia Marsilio and Yan, {Xiao Jie} and Sophia Yancopoulos and Gregory Hayes and Claire Emson and Murphy, {Elizabeth J.} and Hellerstein, {Marc K.} and Cristina Sison and Kaufman, {Matthew S.} and Kolitz, {Jonathan E.} and Allen, {Steven L.} and Rai, {Kanti R.} and Ivana Ivanovic and Dozmorov, {Igor M.} and Sergio Roa and Scharff, {Matthew D.} and Wentian Li and Nicholas Chiorazzi",
year = "2011",
month = "11",
doi = "10.2119/molmed.2011.00360",
language = "English (US)",
volume = "17",
pages = "1374--1382",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "11",

}

TY - JOUR

T1 - Intraclonal complexity in chronic lymphocytic leukemia

T2 - Fractions enriched in recently born/divided and older/quiescent cells

AU - Calissano, Carlo

AU - Damle, Rajendra N.

AU - Marsilio, Sonia

AU - Yan, Xiao Jie

AU - Yancopoulos, Sophia

AU - Hayes, Gregory

AU - Emson, Claire

AU - Murphy, Elizabeth J.

AU - Hellerstein, Marc K.

AU - Sison, Cristina

AU - Kaufman, Matthew S.

AU - Kolitz, Jonathan E.

AU - Allen, Steven L.

AU - Rai, Kanti R.

AU - Ivanovic, Ivana

AU - Dozmorov, Igor M.

AU - Roa, Sergio

AU - Scharff, Matthew D.

AU - Li, Wentian

AU - Chiorazzi, Nicholas

PY - 2011/11

Y1 - 2011/11

N2 - The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth of minor subclones with more dangerous genomic abnormalities or with self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured B-cell kinetics in vivo by quantifying deuterium ( 2H)-labeled cells as an indicator of a cell that had divided. Separating CLL clones on the basis of reciprocal densities of chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster designation 5 (CD5) revealed that the CXCR4 dimCD5 bright (proliferative) fraction contained more 2H-labeled DNA and hence divided cells than the CXCR4 brightCD5 dim (resting) fraction. This enrichment was confirmed by the relative expression of two cell cycle-associated molecules in the same fractions, Ki-67 and minichromosome maintenance protein 6 (MCM6). Comparisons of global gene expression between the CXCR4 dimCD5 bright and CXCR4 brightCD5 dim fractions indicated higher levels of pro-proliferation and antiapoptotic genes and genes involved in oxidative injury in the proliferative fraction. An extended immunophenotype was also defined, providing a wider range of surface molecules characteristic of each fraction. These intraclonal analyses suggest a model of CLL cell biology in which the leukemic clone contains a spectrum of cells from the proliferative fraction, enriched in recently divided robust cells that are lymphoid tissue emigrants, to the resting fraction enriched in older, less vital cells that need to immigrate to lymphoid tissue or die. The model also suggests several targets preferentially expressed in the two populations amenable for therapeutic attack. Finally, the study lays the groundwork for future analyses that might provide a more robust understanding of the development and clonal evolution of this currently incurable disease. © 2011 The Feinstein Institute for Medical Research.

AB - The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth of minor subclones with more dangerous genomic abnormalities or with self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured B-cell kinetics in vivo by quantifying deuterium ( 2H)-labeled cells as an indicator of a cell that had divided. Separating CLL clones on the basis of reciprocal densities of chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster designation 5 (CD5) revealed that the CXCR4 dimCD5 bright (proliferative) fraction contained more 2H-labeled DNA and hence divided cells than the CXCR4 brightCD5 dim (resting) fraction. This enrichment was confirmed by the relative expression of two cell cycle-associated molecules in the same fractions, Ki-67 and minichromosome maintenance protein 6 (MCM6). Comparisons of global gene expression between the CXCR4 dimCD5 bright and CXCR4 brightCD5 dim fractions indicated higher levels of pro-proliferation and antiapoptotic genes and genes involved in oxidative injury in the proliferative fraction. An extended immunophenotype was also defined, providing a wider range of surface molecules characteristic of each fraction. These intraclonal analyses suggest a model of CLL cell biology in which the leukemic clone contains a spectrum of cells from the proliferative fraction, enriched in recently divided robust cells that are lymphoid tissue emigrants, to the resting fraction enriched in older, less vital cells that need to immigrate to lymphoid tissue or die. The model also suggests several targets preferentially expressed in the two populations amenable for therapeutic attack. Finally, the study lays the groundwork for future analyses that might provide a more robust understanding of the development and clonal evolution of this currently incurable disease. © 2011 The Feinstein Institute for Medical Research.

UR - http://www.scopus.com/inward/record.url?scp=82855177892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82855177892&partnerID=8YFLogxK

U2 - 10.2119/molmed.2011.00360

DO - 10.2119/molmed.2011.00360

M3 - Article

C2 - 21968788

AN - SCOPUS:82855177892

VL - 17

SP - 1374

EP - 1382

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 11

ER -